Is the efficacy of Anamorelin reliable and how effective is it?

Anamorelin (Anamorelin) is an innovative drug that has attracted widespread attention in the field of tumor supportive care in recent years. It is mainly used for the treatment of cancer-related cachexia (Cancer Cachexia), especially in patients with non-small cell lung cancer (NSCLC). This drug is a selective ghrelin receptor agonist. It activates the hunger center of the hypothalamus by simulating the effect of endogenous ghrelin, thereby enhancing appetite, promoting weight gain, and improving the patient's nutritional status and quality of life to a certain extent. Anamorelin's mechanism of action is different from traditional nutritional supplement therapy. It does not simply provide caloric intake, but uses the central regulatory mechanism as the core to improve tumor-related metabolic abnormalities and energy balance disorders.

As to whether the efficacy of Anamorelin is reliable, the international medical community has conducted many studies to verify its clinical effect, especially in improving the lean body mass (LBM, lean body mass) and appetite of cancer patients, which has shown relatively consistent efficacy. Two large multi-center, double-blind, randomized controlled phase III clinical studies, represented by ROMANA 1 and ROMANA 2, conducted a 12-week observation on patients with advanced non-small cell lung cancer. The results showed that compared with the placebo group, patients treated with anamorelin had a significant improvement in fat-free body mass and an improvement in subjective appetite scores. This shows that the drug can effectively help patients maintain their physical status during anti-cancer treatment. However, in these two studies, no significant improvement was observed in indicators that directly measure physical function such as hand grip strength (HGS), suggesting that its role in improving muscle strength is not obvious yet and may need to be used in conjunction with rehabilitation training or other comprehensive intervention methods to obtain better overall effects.

Clinical studies from Japan have further strengthened the reliability of anamorelin’s efficacy. For example, a Phase II study conducted in Japan showed that anamorelin can not only significantly improve fat-free body mass, but also improve patients' Karnofsky Function Score (KPS) and Quality of Life Score (QoL), which has real and direct benefits for patients with cancer cachexia. Cancer cachexia is a complex multifactorial syndrome. Its pathogenesis involves inflammation, hormone imbalance, metabolic disorders and abnormal central nervous system regulation. Therefore, treatment methods must have multi-dimensional regulatory capabilities. Anamorelin indirectly acts on the hypothalamus, gastrointestinal tract, and peripheral metabolic system by simulating ghrelin signals to achieve a comprehensive action path of enhancing appetite, promoting protein synthesis, and reducing muscle breakdown. This makes it one of the few treatment options currently supported by good evidence in the field of cancer cachexia.

However, the long-term maintenance and broad adaptability of anamorelin's effects are still under investigation. Current research focuses on the specific population of patients with non-small cell lung cancer, and there is still a lack of sufficient data on the adaptability and effect for patients with other types of tumors (such as pancreatic cancer, gastric cancer, or breast cancer). In addition, since cancer cachexia often develops with advanced disease, its treatment goals focus more on alleviating symptoms and improving quality of life rather than prolonging overall survival. Therefore, in the evaluation of the efficacy of anamulin, it also pays more attention to the improvement of patients' subjective feelings, such as appetite improvement, weight change, and recovery of activity ability, rather than tumor shrinkage or survival prolongation in the traditional sense.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/